First slide

In order to accelerate development of therapies, Pfizer Inc. has acquired Amplyx Pharmaceuticals, Inc. The San Diego, California, based Amplyx Pharmaceuticals, Inc., is a privately-held company dedicated to the development of therapies for debilitating and life-threatening diseases.

  • Amplyx’s lead compound, Fosmanogepix (APX001), is a novel investigational asset under development for the treatment of invasive fungal infections.
  • In addition to Fosmanogepix, with this acquisition, Pfizer has secured ownership of Amplyx’s early-stage pipeline that includes potential antiviral (MAU868) and antifungal (APX2039) therapies.
  • Fosmanogepix has a novel mechanism of action with the potential to target fungal strains resistant to standard of care therapy.

The prominent deals and partnerships by Pfizer are featured below:

March 2021: To boost biologics manufacturing in China, WuXi Biologics announced to acquire DS and DP manufacturing facilities from Pfizer. The deal helps will boost the commercial Drug Substance (DS) and Drug Product (DP) capacities for WuXi Biologics to address surging manufacturing demands.

Nov 2020: The global pharmaceutical company, Pfizer Inc. in association with BioNTech SE announced the execution of an agreement with the U.S.
Department of Health and Human Services and the Department of Defense to provide 300 million doses of a vaccine for COVID-19 in 2021

July 2020: Pfizer Inc. and BioNTech SE announced an agreement with the United Kingdom to supply 30 million doses of their BNT162 mRNA-based vaccine candidate against SARS-CoV-2, currently in development, subject to clinical success and regulatory approval. Financial details of the agreement were not disclosed, but the terms were based on the timing of delivery and the volume of doses.

July 2020: Pfizer Inc. had pledged $100 million to the new Antimicrobial Resistance (AMR) Action Fund, to help address the significant global public health need for new antibiotics due to the rapid rise of antibiotic-resistant infections.

Dec 2019: Theravance Biopharma Ireland Limited, a subsidiary of Theravance Biopharma, Inc. and Pfizer Inc. announced that the companies had been entered into a global license agreement for Theravance Biopharma’s preclinical program for skin-targeted, locally-acting pan-Janus kinase (JAK) inhibitors that can be rapidly metabolized.

About Pfizer
Pfizer, headquartered in New York, United States, is a global pharmaceutical corporation. The company involves in discovery, development and manufacturing of health care products globally. Its global portfolio includes medicines and vaccines as well as many of the world’s best?known consumer health care products.

Prominent Global Investors

View all

Related News